- Company
- Oral AML drug Onureg can be prescribed at general hospitals
- by Eo, Yun-Ho Jun 30, 2023 06:01am
- The oral acute myeloid leukemia (AML) treatment ‘Onureg’ can now be prescribed at general hospitals in Korea. According to industry sources, BMS Korea’s new AML drug Onureg tablet (azacytidine) has passed the drug committees of Asan Medical Center and Seoul National University Bundang Hospital and is also undergoing landing processes
- Company
- Unlisted Trajenta patents hinder early release of generics
- by Kim, Jin-Gu Jun 29, 2023 05:56am
- The patent challenges made for the early release of antidiabetic ‘Trajenta (linagliptin)’ is going through a rough patch. The patents that the original company registered with KIPO but not with the MFDS are acting as obstacles. For the generics companies that filed patent challenges, a prolonged dispute is now inevitable as they would hav
- Company
- SK Plasma supplies 39 billion worth of blood products
- by Jun 29, 2023 05:56am
- SK Plasma announced on the 28th that it will begin full-fledged production this month after receiving product approval for blood products (albumin and immunoglobulin) from the Singapore Health Authority (HSA). The company will independently supply a total of 30 million dollars (39 billion won) worth of blood derivatives over the next six yea
- Company
- RET-targeted Retevmo lands in Big 5 general hospitals in KOR
- by Eo, Yun-Ho Jun 29, 2023 05:56am
- The RET-targeted anticancer therapy ‘Retevmo’ may now be prescribed at the Big 5 hospitals in Korea. According to industry sources, Lilly Korea’s Retevmo (selpercatinib) passed the drug committees of all the Big 5 tertiary hospitals in Korea - Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary’s Hospital, Seoul
- Company
- Imjudo, the No. 8 immune anti-cancer drug, landed
- by Jun 28, 2023 05:53am
- The 8th and 2nd immuno-anticancer drug with CTLA-4 inhibitory mechanism has appeared in Korea. After more than 10 years of development, AstraZeneca created the first immuno-oncology + immuno-oncology combination option in liver cancer. According to the pharmaceutical industry on the 26th, the Ministry of Food and Drug Safety recently granted
- Company
- Generic for Paxlovid PQ certification for 1 year
- by Jun 28, 2023 05:53am
- Among the 36 pharmaceutical companies that have introduced Paxlovid's generic license for an edible COVID-19 treatment, some companies are attempting World Health Organization (WHO) pre-qualification (PQ) certification. Each pharmaceutical company is expected to obtain PQ certification even after the COVID-19 emergency is lifted and supply me
- Company
- Seize the promising target Claudin market
- by Jun 28, 2023 05:53am
- Claudin 18.2 (CLDN18.2) is emerging as a new alternative for gastric cancer with a poor prognosis, and a development boom is brewing among global pharmaceutical companies. Various new drugs such as cell therapy drugs and bispecific antibodies have been put to the test in order to preoccupy this market, which is a communist communist country.
- Company
- SK bioscience collaborates with the Doherty Institute
- by Jun 28, 2023 05:53am
- SK bioscience announced on the 27th that it had signed a research cooperation agreement with the Peter Doherty Institute for Infection and Immunity in Australia for global influenza prevention and response. The Peter Doherty Institute for Infection and Immunity is an infectious disease research institute affiliated with the University of Melb
- Company
- Reimb progress of 2 NMOSD drugs receive attention in 2H
- by Eo, Yun-Ho Jun 28, 2023 05:52am
- Whether the two optic nerve sclerosis drugs that have remained non-reimbursed for a long time in Korea will be reimbursed this time is receiving attention. According to industry sources, discussions are ongoing to introduce the agenda on reimbursing the neuromyelitis optica spectrum disorder (NMOSD) indication of ’Soliris (eculizumab)’
- Company
- B-cell lymphoma drug Polivy applies for reimb again
- by Eo, Yun-Ho Jun 27, 2023 05:47am
- The B-cell lymphoma drug ‘Polivy’ is reattempting to receive reimbursement in Korea. This time, the company applied for Polivy’s reimbursement with a different indication. According to industry sources, Roche Korea submitted an application for the reimbursement of its Diffuse Large B-Cell Lymphoma (DLBCL) treatment Polivy (polatuzumab
